Did you Spark Hope?
Dear Friends,We all know that 2020 has been a year of great challenges that have tested our resilience. In the midst of all this, our headline for this eUpdate is a celebration of the collective impact of the NETRF community. We are thrilled to announce the completion of NETRF’s $10 million Spark Hope campaign! YOU DID IT—achieving the goal for the most ambitious fundraising campaign in NETRF history!This has been a tremendous effort and deserves celebration. Nearly 4,000 donors have given $5 million to NETRF since the campaign began in July 2018. Your gifts were so generously matched by a $5 million gift from the Margie and Robert E. Petersen Foundation. Every gift, small and large, was meaningful because it brought us closer to the goal of ensuring NETRF can fund vital, innovative NET research for years to come.
| |
| See the difference $10 million makes.
Click below to hear from researchers, NETRF Board Members, and Scientific Advisors in this Thank You video.
| |
On behalf of our Board, staff, scientific advisors, and all those with neuroendocrine cancer, we are grateful for your support and confidence in our work.
Thank you so much for SPARKING HOPE!
| |
Elyse Gellerman
Chief Executive Officer
| |
Simplified Giving with a Donor-Advised Fund To make it even easier to give using a donor-advised fund (DAF), NETRF now offers DAF DIRECT, a free and easy-to-use way to start your gift right now, from the NETRF website. You can make a charitable gift to NETRF anywhere or anytime to advance NET research. (MORE)
| |
|
Improving PRRT for pNETs
With a new research award, Xavier Keutgen, MD, University of Chicago, will study a subset of pancreatic NETs (pNETs) that respond better to radiotherapy than most pNETs.
“This research project will help me collect data studying the apparent intrinsic radiosensitivity that a subset of pNETs has and apply this knowledge to improve current radiation therapies, including PRRT," said Dr. Keutgen.
The two-year, $100,000 grant from the North American Neuroendocrine Tumor Society (NANETS), funded by NETRF, will support the search for explanations to the apparent increase in tumor cell death in the subtype. (MORE)
| |
New PET Tracer Approved by FDA
A new PET scan tracer, called Detectnet™ (copper Cu 64 dotatate) manufactured by Curium, may help expand access to diagnostic imaging for NET patients. A half-life of 12.5 hours, as opposed to an hour or so for existing options, makes it easier to transport and store. “Our unique production capabilities and distribution network allow us to deliver to any nuclear pharmacy, hospital, or imaging center its full dosing requirements first thing in the morning, to provide scheduling flexibility to the institution and its patients,” said Dan Brague, Curium CEO, North America. (MORE)
| |
Saturday, Oct 10
9 AM to 1 PM ET
Register Now for Virtual Conference
We will take off where most conferences end. Join us as we peel back the curtain to look at the more complicated choices and challenges faced by those living with neuroendocrine cancer. Leading experts on NETs offer an in-depth look at the risks and benefits of advanced treatment options that individuals must consider when making decisions about care planning. (MORE)
| |
NETWise Podcast Looks at Lung NETs
Initially, symptoms may be dismissed as asthma or allergies. A person may experience a cough that just doesn't quit or regular wheezing and shortness of breath. Advanced testing, however, sometimes reveals neuroendocrine tumors in the lungs. In this special episode of NETRF's NETWise podcast, we look at the challenges of diagnosing and treating NETs in the respiratory system. Hear about the latest developments in treatments for this common tumor site. (MORE)
| |
Plus, NETQuiz #11 on Symptom Management
| |
Recognizing Carcinoid Syndrome
Diarrhea. Cramping. Facial flushing. These symptoms can come together as Carcinoid Syndrome, causing significant disruption in daily life. In new information added to NETRF.org, we help you understand the most common and the most serious symptoms of Carcinoid Syndrome. (MORE)
| |
NETs & COVID-19
What have we learned about NETS and COVID-19 in the last six months? Scientists are analyzing data about the threats posed by the virus to those living with cancer in real-time. In this videotaped interview, we sit down with NETRF Board Member and Intermountain Healthcare oncologist Mark Lewis, MD, to review the latest facts. Learn about the best ways to protect yourself while settling into a new daily routine. (MORE)
| |
#RareCancerDay
On September 30, NETRF will join with other members of the rare disease community to increase awareness about the role of genetic testing in treating cancer. (MORE)
| |
| This issue of NETRF's eUpdate has been sponsored in part by:
| |
|
|
|
|
